Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Intangibles (2016 - 2025)

Plus Therapeutics has reported Intangibles over the past 16 years, most recently at $333000.0 for Q4 2025.

  • Quarterly Intangibles fell 29.0% to $333000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $333000.0 through Dec 2025, down 29.0% year-over-year, with the annual reading at $333000.0 for FY2025, 29.0% down from the prior year.
  • Intangibles was $333000.0 for Q4 2025 at Plus Therapeutics, down from $374000.0 in the prior quarter.
  • Over five years, Intangibles peaked at $557000.0 in Q2 2024 and troughed at $33000.0 in Q1 2024.
  • The 5-year median for Intangibles is $103500.0 (2022), against an average of $204700.0.
  • Year-over-year, Intangibles plummeted 58.23% in 2024 and then skyrocketed 1218.18% in 2025.
  • A 5-year view of Intangibles shows it stood at $51000.0 in 2021, then surged by 84.31% to $94000.0 in 2022, then plummeted by 55.32% to $42000.0 in 2023, then soared by 1016.67% to $469000.0 in 2024, then decreased by 29.0% to $333000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Intangibles are $333000.0 (Q4 2025), $374000.0 (Q3 2025), and $401000.0 (Q2 2025).